Results 1 to 10 of about 2,897,878 (123)
Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations [PDF]
Haematologica, 2015 The JAK2 V617F mutation, the thrombopoietin receptor MPL W515K/L mutation and calreticulin (CALR) mutations are mutually exclusive in essential thrombocythemia and support a novel molecular categorization of essential thrombocythemia.
Carla Al Assaf +12 more
doaj +2 more sources
Essential thrombocythemia, hemolytic anemia and hepatic cirrhosis: Could there be an association? [PDF]
Hematology Reports, 2018 Vascular events are the most common clinical complication of essential thrombocythemia, leading to sign and symptoms of this disease. There are various sign and symptoms of essential thrombocythemia, such as thrombosis in artery or vein, and enlarged ...
Nata Pratama Hardjo Lugito +4 more
doaj +2 more sources
Journal of Nepal Medical Association, 2022 Introduction: Essential thrombocythemia, a myeloproliferative condition with an increased number of circulating platelets, is a rare hematological malignancy. The aim of the study is to find out the prevalence of essential thrombocythemia among patients
Sanjit Kumar Sah +9 more
doaj +1 more source
Orphanet Journal of Rare Diseases, 2007 Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD) characterized by a sustained elevation of platelet number with a tendency for thrombosis and hemorrhage. The prevalence in the general population is approximately 30/100,000.
Brière Jean B
doaj +1 more source
Retinal neovascularization in the setting of -mutation positive essential thrombocythemia
SAGE Open Medical Case Reports, 2023 Patients with Calreticulin ( CALR ) mutation positive essential thrombocythemia are often thought of as having a “low-risk” of thrombotic complications.
Stanton P Heydinger +2 more
doaj +1 more source
Haematologica, 2008 We analyzed the effect of hydroxyurea on the JAK2V617F allelic ratio (%JAK2V617F), measured in purified blood granulocytes, of patients with polycythemia vera and essential thrombocythemia.
François Girodon +8 more
doaj +1 more source
SAGE Open Medical Case Reports, 2021 Essential thrombocythemia is one of the famous diseases under the category of myeloproliferative disorder. It is an end result of a genetic mutation of one or more of the most frequent oncogenes such as Janos kinase 2 (JAK2), MPL proto-oncogene ...
Rehab Y AL-Ansari +3 more
doaj +1 more source
Pregnancy with Essential Thrombocythemia: A Case Report
Taiwanese Journal of Obstetrics & Gynecology, 2004 Objective: We describe a woman with essential thrombocythemia (ET) who experienced a successful pregnancy with no specific treatment. Case Report: A 30-year-old primiparous female was incidentally found to have ET with no specific symptoms at a ...
Yin-Jou Chou +3 more
doaj +1 more source
Recurrent thrombosis of splanchnic and lower extremity arteries with essential thrombocythemia
SAGE Open Medical Case Reports, 2019 Essential thrombocythemia is a myeloproliferative neoplasm characterized by platelet aggregation and thrombosis. Clinically, essential thrombocythemia increases the risk of both thrombosis and bleeding. Essential thrombocythemia is more involved in micro-
Sung Min Jung, Heungman Jun
doaj +1 more source
Haematologica, 2019 Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera is difficult because of shared mutation and phenotypic characteristics. The World Health Organization suggested hemoglobin and hematocrit values to diagnose polycythemia vera (PV),
Richard T. Silver, Spencer Krichevsky
doaj +1 more source